RecurX Bio's phenotypic microfluidic assay captures the most deadly cells responsible for cancer metastasis, rapid spread and recurrence. We are developing a laboratory test to determine the best cancer drugs to stop these deadly cells before treatment begins. Before the RecruX Bio technology, there were few laboratory tools to provide oncologists with sufficient information to know which drugs will work best for an individual patient. Current practice is to choose based mainly on which drug has the least side effects and then wait to see if the cancer responds. This treatment strategy can cause the patient serious unnecessary side effects from drugs that don't work, and cost valuable time in the race to stop the cancer. Our technology can provide personalized information to oncologists within a couple of days. We are also providing services to pharmaceutical companies to assist in more effective drug development. 97%+ cancer drugs fail in human clinical trials, in part because the laboratory models do not accurately represent what happens in the body during metastasis. Better technology is necessary to bring much needed drugs for both early and late stage cancer to market. New drug discovery can occur faster, less expensively and with greater success by using the RecurX Bio technology to screen and select drug candidates for preclinical and clinical testing and by identifying the unique druggable targets in the most deadly cells captured using the RecurX Bio technology. Our research in breast cancer and glioblastoma has been published, and we are developing the test for additional solid and liquid tumors. See Yankaskas, et al. A microfluidic assay for the quantification of the metastatic propensity of breast cancer Nat Biomed Eng 3, 452 - 465 (2019); Wong, et al. A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma. Nat Biomed Eng (2020) https://doi.org/10.1038/s41551-020-00621-9